Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Executive Summary
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
You may also be interested in...
Surprise, Skepticism And Scorn: Reaction To Rumored Haleon Interest In Sanofi CHC
Analysts share their thoughts on reports that Haleon is interested in acquiring Sanofi Consumer Healthcare to enhance its market leading position.
Euro Q2 Consumer Health Earnings Preview: Volatility, Delay, Upturn And Goodbye
Major Europe-based consumer health players Bayer, Sanofi, Reckitt and GSK feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2022 results over the coming weeks.
Euro Q1 Consumer Health Earnings Preview: Sanofi, Reckitt, GSK And Bayer
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.